This product is a non-sulfonylurea insulin secretagogue. It specifically binds to the 36KDA protein on the ATP-dependent potassium ion channel outside the pancreatic beta cell membrane, closing the potassium channel, depolarizing the beta cell, opening the calcium channel, and causing calcium ions to flow in, thus promoting insulin secretion. It works faster than sulfonylureas, so it has a faster effect in lowering blood sugar after a meal.

Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on functional beta cells in the pancreatic islets. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, increases calcium influx, and induces beta cells to secrete insulin. After oral administration of repaglinide, patients with type 2 diabetes experience an insulin secretion response within 30 minutes after a meal, causing lower blood sugar levels during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that taking 0.5-4 mg of repaglinide in patients with type 2 diabetes reduces blood sugar levels in a dose-dependent manner.

Unspecified

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

The specific pharmacological effects are not clearly described from the above information